EpiQuil is an Australian medical technology company founded in 2025, building on more than five years of foundational research and early development in advanced drug-delivery systems.

We were established around a simple conviction: how a medicine is delivered can materially shape the experience of care. Route of administration, dosing practicalities, tolerability, and usability can influence how consistently treatments are used across clinical settings.

Our work focuses on areas of high unmet medical need, where alternative routes of administration continue to be actively explored and where delivery technologies are designed to support reliability and usability.

From the outset, our programs have followed a rigorous, stepwise development pathway. We collaborate with clinicians, researchers, and development partners to generate preclinical and technical evidence on system design, performance, usability, and reproducibility. Development activities are guided by pharmaceutical quality principles and relevant medical device standards, with evaluation progressing through defined stages as programs mature.

Our team brings together experience in pharmacy, clinical research, pharmaceutical development, and medical technology. This multidisciplinary foundation helps translate early scientific concepts into structured development programs aligned with international expectations for quality, safety, and clinical investigation.

Guided by scientific integrity and disciplined execution, EpiQuil’s ambition is to advance transdermal delivery technologies through responsible development and evidence generation, with patient safety as the constant priority.

Our technologies are under development and are not currently available for supply.